Additionally, somatic mutations in LRP1B correlate with tumor mutation burden status in several cancers, e.g., nasopharyngeal carcinoma [45], and LRP1B has been proposed as a single gene surrogate to this status (mutational load, in other words, [46]), which correlates with response to immunotherapy. This evidence concerns the gene LRP1B and neoplasm.